Priya cmi

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
CHRONIC LIVER DISEASES THERAPEUTICS MARKET
ANALYSIS

• Chronic Liver Diseases Therapeutics Market, by
  Therapy Type (Anti-Rejection Drugs/Immunosuppressa
  nts, Chemotherapy Drugs, Targeted therapy,
  Vaccines, Anti-Viral Drugs, Immunoglobulins, and
  Corticosteroids), By Distribution Channel
  (Hospital Pharmacies, Retail Pharmacies, and
  Online Pharmacies), and by Region (North America,
  Latin America, Europe, Asia Pacific, Middle East,
  and Africa) - Size, Share, Outlook, and
  Opportunity Analysis, 2020 - 2027

3

• The global chronic liver diseases therapeutics
  market is expected to witness significant growth
  during the forecast period owing to the
  increasing prevalence of liver disease. As the
  main reason causing cirrhosis is high consumption
  of alcohol. For instance, in 2015, according to
  the National Survey on Drug Use and Health
  (NSDUH) data, around 88,000 people (around 62,000
  men and 26,000 women) died due to alcohol-related
  causes annually, which makes alcohol consumption
  the fourth leading preventable cause of death in
  the U.S.
• Similarly, the high number of patients with
  chronic liver disease such as cirrhosis is
  contributing to the growth of the global chronic
  liver disease therapeutic market.
• Global Chronic Liver Diseases Therapeutics
  Market - Impact of Coronavirus (Covid-19)
  Pandemic
• The spread of coronavirus has negatively impacted
  the global chronic liver disease therapeutics
  market. The outbreak of this virus has hindered
  the growth of the global market. The U.S has the
  highest number of corona patients which is
  expected to impact the countrys economic
  condition. The U.S is high potential market for
  the pharmaceuticals industry, and the economic
  slowdown of the U.S economy is likely to impact
  the market for pharmaceutical drugs

4

• Similarly, markets in India, Brazil, Russia and
  other economies are also suffering due to
  Covid-19 attack that is expected to impact on
  lowering the pharmaceutical growth.  Furthermore,
  due to COVID-19 pandemic, hospitals are closed in
  containment zones, that has slowed the hospital
  visits and stabilized the demand for therapeutic
  drugs of chronic liver diseases.
• The global chronic liver diseases therapeutics
  market is estimated to be valued at US 12.8 Bn
  in 2020 and is expected to exhibit a CAGR of
  9.7 during the forecast period (2020-2027).

5
Figure 1. Global Chronic Liver Diseases
Therapeutics Market Share () Analysis in 2020,
By Therapy Type
6

• Global Chronic Liver Diseases Therapeutics Market
  - Restraints
• Side effects and risks associated with liver
  disease therapeutics are expected to hinder
  growth of the global liver disease therapeutics
  market. The side effects associated with the use
  of liver therapeutics are nausea, headache, fever
  loss of appetite, and drug-induced liver disease.
  Moreover, availability of alternate treatment
  procedures such as organ transplantation and
  liver resection are also expected to limit growth
  of the market.

7
(No Transcript)
8

• Market Opportunities
• Increasing research and development of
  immunotoxins is expected to offer lucrative
  growth opportunities to players operating in the
  global chronic liver disease therapeutics market.
  For instance, GPC3 is a cell surface heparan
  sulfate proteoglycan that is overexpressed in
  hepatocellular carcinoma. Anti-GPC3 immunotoxins
  can be effective in the treatment of human
  hepatocellular carcinoma.
• Moreover, clinical trials of new therapies are
  also expected to aid the market growth. For
  instance, in March 2018, the U.S. FDA granted
  Orphan Drug Designation for Protagonist
  Therapeutics, Inc.s PTG-300 a subcutaneous
  injectable in clinical development stage for the
  potential treatment of beta-thalassemia and liver
  fibrosis

9
Figure 2. Global Chronic Liver Diseases
Therapeutics Market Value (US Mn) Y-o-Y Growth
(), 2017-2027
10

• Global Chronic Liver Diseases Therapeutics Market
  Regional Analysis
• On the basis of region, the global chronic liver
  disease therapeutics market is segmented into
  North America, Latin America, Europe, Asia
  Pacific, Middle East, and Africa.
• The market in North America is expected to
  witness significant growth owing to presence of
  major players in the region. Players are focused
  on collaboration strategies to expand their
  product portfolio. For instance, in April 2020,
  Alnylam Pharmaceuticals, Inc. collaborated with
  Dicerna Pharmaceuticals, Inc. for development and
  commercialization of investigational RNAi
  therapeutics for the treatment of alpha-1
  antitrypsin deficiency-associated liver disease.

11

• Global Chronic Liver Diseases Therapeutics Market
  - Competitive Landscape
• Key players operating in the global chronic liver
  disease therapeutics market are Astellas Pharma
  Inc., Bristol-Myers Squibb, Gilead Sciences,
  GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd.,
  Merck Co. Inc., Novartis AG, Sanofi S.A, Pfizer
  Inc., Takeda Pharmaceutical, Valeant
  Pharmaceuticals, Watson Pharmaceuticals, Inc.,
  Theratechnologies Inc., Alnylam Pharmaceuticals,
  Inc., Protagonist Therapeutics, Inc., Dicerna
  Pharmaceuticals, Inc., Endo International,
  Provectus Biopharmaceuticals Inc., and MAX
  BioPharma, Inc.

12

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Referencehttps//www.coherentmarketinsights.com/ma
  rket-insight/chronic-liver-diseases-therapeutics-m
  arket-4047

13
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

14
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

15

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/